Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic Neuropathy

Paul T. Finger

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Purpose: To evaluate intravitreal bevacizumab treatment for radiation optic neuropathy (RON). Design: Interventional case report. Methods: At The New York Eye Cancer Center, a patient symptomatic of decreased vision because of RON was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included visual acuity, appearance of the optic nerve, fundus photography, angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO). Results: Within one week, her vision improved from 20/32 to 20/20 with a reduction in optic disk hemorrhage. At six weeks, evidence of both decreased hemorrhage and optic disk edema was documented by photography, angiography, and OCT/SLO. At the three and five-month follow-up visits, the hemorrhages resolved, and her disk margins were sharp. There were no ocular or systemic side effects. Conclusions: Intravitreal bevacizumab was tolerated, improved vision, and reduced hemorrhage as well as optic disk edema (angiographic leakage). Anti-VEGF therapy (e.g. bevacizumab) should be investigated for both ocular and nonocular radiation neuropathy.

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalAmerican Journal of Ophthalmology
Issue number2
StatePublished - Feb 2007
Externally publishedYes


Dive into the research topics of 'Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic Neuropathy'. Together they form a unique fingerprint.

Cite this